BioAge begins Phase 1 study of BGE-102 NLRP3 inhibitor

BioAge Labs, in partnership with HitGen, has initiated a Phase 1 clinical trial of BGE-102, a novel, orally available small-molecule inhibitor of NLRP3 that penetrates the brain, according to the company. The study will evaluate single and multiple ascending doses (SAD/MAD), with initial SAD data expected by year-end. The inhibitor was developed from compounds identified […] The post BioAge begins Phase 1 study of BGE-102 NLRP3 inhibitor appeared first on Longevity.Technology.